pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›PREGABALIN
drug
save

PREGABALIN

Marketedupdated 6mo ago
by RK Pharma Inc
Approved
annual revenue · 2024–2024peak $383M
2024: $383M2024$383M
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval58 co-mentions · 29 sources
  • drugpregabalin ER29 co-mentions · 29 sources
  • drugLyrica29 co-mentions · 29 sources
  • drugpregabalin CR29 co-mentions · 29 sources
  • tagSmall Molecule29 co-mentions · 29 sources
  • drugpregabalin SR29 co-mentions · 29 sources
  • companyLupin Ltd3 co-mentions · 3 sources
  • companyStrides Pharma Inc3 co-mentions · 3 sources

all catalysts(14)

approval · 14
Apr 13, 2021
approval
6y ago
PREGABALIN — FDA approval
PREGABALIN
→
Apr 13, 2021
approval
6y ago
PREGABALIN — FDA approval
PREGABALIN
→
Mar 8, 2022
approval
5y ago
PREGABALIN — FDA approval
PREGABALIN
→
May 3, 2022
approval
5y ago
PREGABALIN — FDA approval
PREGABALIN
→
Apr 26, 2023
approval
4y ago
PREGABALIN — FDA approval
PREGABALIN
→
Jul 21, 2023
approval
3y ago
PREGABALIN — FDA approval
PREGABALIN
→
May 30, 2024
approval
2y ago
PREGABALIN — FDA approval
PREGABALIN
→
Dec 9, 2024
approval
2y ago
PREGABALIN — FDA approval
PREGABALIN
→
Sep 30, 2025
approval
1y ago
PREGABALIN — FDA approval
PREGABALIN
→
Feb 2, 2026
approval
10mo ago
PREGABALIN — FDA approval
PREGABALIN
→
Feb 3, 2026
approval
10mo ago
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
9mo ago
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
9mo ago
PREGABALIN — FDA approval
PREGABALIN
→
Mar 30, 2026
approval
8mo ago
PREGABALIN — FDA approval
PREGABALIN
→
view all 14 catalysts →

Trials studying PREGABALIN

  • phase1Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participantsnot yet recruitingn=11
  • phase2Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathyrecruitingn=300
  • phase1A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Painrecruitingn=168
  • phase2Y-4 to Treat the Postherpetic Neuralgiarecruitingn=160
  • phase3Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathyrecruitingn=1,100
  • —A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweatsactive not recruitingn=999
  • phase2Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)completedn=194
  • EP1Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adultscompletedn=20

Patent cliff

source: FDA Orange Book
first barrier falls
May 2, 2027
163 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • May 2, 2027patentUS 10022447*PED163d
  • May 2, 2027patentUS 10022447*PED163d
  • May 2, 2027patentUS 10022447*PED163d
  • May 2, 2027patentUS 8945620*PED163d
  • May 2, 2027patentUS 8945620*PED163d
  • May 2, 2027patentUS 8945620*PED163d
  • May 2, 2027patentUS 9144559*PED163d
  • May 2, 2027patentUS 9144559*PED163d
  • May 2, 2027patentUS 9144559*PED163d
  • Nov 2, 2026method-of-use (U-2136)US 10022447
  • Nov 2, 2026method-of-use (U-2136)US 10022447
  • Nov 2, 2026method-of-use (U-2136)US 10022447
  • Nov 2, 2026formulationUS 8945620
  • Nov 2, 2026formulationUS 8945620
  • Nov 2, 2026formulationUS 8945620
  • Nov 2, 2026formulationUS 9144559
  • Nov 2, 2026formulationUS 9144559
  • Nov 2, 2026formulationUS 9144559

News(1)

  • Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
    While psychedelic drugs may be capturing all the attention when it comes to finding fresh ways to treat neuropathic pain, research with mice has suggested a peptide approach may also be effective.
    fiercebiotech · 1mo ago
brand
PREGABALIN
generic
PREGABALIN
indication
Diabetic Peripheral Neuropathy
phase
marketed
approved
2004-12-30
Data sources
openFDA · ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?